Retatrutide: what Phase 1b, Phase 2, and the TRIUMPH program have actually measured

What the studies have documented — in plain terms

Retatrutide is an investigational drug — meaning it is not yet approved or available by prescription anywhere. Eli Lilly developed it. It is in Phase 3 clinical trials (the TRIUMPH program) as of 2026. Nobody can prescribe it or dispense it outside of those trials.

What retatrutide does in studies is notable. It activates three hormone receptors at once — GLP-1 (a gut hormone that reduces appetite), GIP (another gut hormone that affects insulin and fat), and glucagon (a pancreatic hormone that raises energy burn). No prior approved weight-management drug has done all three simultaneously. In a large 48-week trial, the highest dose studied produced a mean 24.2% body-weight reduction ^[1]. That figure comes from a peer-reviewed Phase 2 trial published in the New England Journal of Medicine.

Retatrutide has about a 6-day half-life — meaning it clears the body slowly enough to be given once a week ^[4]. That pharmacokinetic profile is the anchor of this site's Retatrutide research lens: dosing windows, what each receptor arm contributes to the timing, and what the clinical trial results tell us about duration and durability.

What to watch for is real and documented: nausea, elevated heart rate, lean-mass considerations. Those are covered on Retatrutide effects.

What does retatrutide do

Retatrutide is a single synthetic peptide — 39 amino acids — that activates the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR) simultaneously ^[3]. Each receptor arm carries a distinct metabolic function. GLP-1 receptor activation suppresses appetite and slows gastric emptying — the brake on caloric intake. GIP receptor activation amplifies insulin secretion after meals and modulates fat-tissue metabolism. Glucagon receptor activation increases energy expenditure and accelerates hepatic lipid metabolism — the throttle on caloric burn.

The combination of appetite suppression plus increased energy expenditure is what distinguishes retatrutide from prior incretin-class agents. A 2024 Cell review characterized triple agonism as producing weight loss rivaling bariatric surgery — up to 20–30% body weight in trial populations ^[13]. The 2025 review in Biomolecules characterized the ~24% figure at 12 mg/48 weeks as a step-change versus prior incretin therapies ^[6].

It is not a GLP-3 agonist. There is no GLP-3 receptor. When this compound is described online as a "GLP-3" drug, that is a misnomer. The three receptors it targets are GIP, GLP-1, and glucagon — each of which is a distinct receptor belonging to the class-B G protein-coupled receptor (GPCR) family.

For a structural account of how does retatrutide work at the receptor level, see the dedicated mechanism page.

Retatrutide results: the Phase 2 trial record

The pivotal Phase 2 data across three indications form the documented evidence base:

Obesity — 338 adults with obesity, 48 weeks, subcutaneous once weekly. At the highest dose studied (12 mg), mean body-weight change was -24.2% versus -2.1% with placebo ^[1]. At 8 mg, the figure was -17.3%. Gastrointestinal adverse events were dose-related and mostly mild to moderate. A dose-dependent increase in heart rate was observed, peaking around 24 weeks.

Type 2 diabetes — 281 adults with T2D, 36 weeks. At 12 mg, HbA1c (glycated hemoglobin — a 3-month blood glucose average) fell by -2.02 percentage points versus -0.01 with placebo at 24 weeks; body weight fell by -16.94% at 36 weeks ^[2].

MASLD (fatty liver) — 98 participants with obesity or overweight and metabolic dysfunction-associated steatotic liver disease (MASLD — the current term for fatty liver tied to metabolic risk factors). At 12 mg, relative liver-fat change at 24 weeks was -82.4% by MRI-PDFF (a non-invasive liver-fat measure). 86% of participants reached normal liver-fat levels (<5%) at that dose ^[5].

All three Phase 2 results are from randomized, double-blind, placebo-controlled trials published in peer-reviewed journals.

Is retatrutide fda approved

No. Retatrutide is not FDA-approved and is not approved by any regulatory agency as of mid-2026. It is an investigational new drug undergoing Phase 3 evaluation. The TRIUMPH-2 (NCT05931367) trial targets obesity with type 2 diabetes ^[8]; TRIUMPH-3 (NCT05882045) targets obesity with cardiovascular disease ^[9]; a dedicated cardiovascular and kidney outcomes trial (NCT06383390) is separately running ^[10]; a head-to-head Phase 3 study of retatrutide versus tirzepatide (NCT06662383) is ongoing ^[11].

Unless and until Eli Lilly files a New Drug Application and the FDA reviews and approves it, retatrutide has no approved indication and cannot legally be prescribed or dispensed outside of clinical trials. This site does not sell, dispense, or prescribe anything. It documents the published research record.

Retatrutide availability and the gray market

Retatrutide is not commercially available. It does not exist as an approved pharmaceutical product. Research-labeled material sold through gray-market channels cannot be verified as authentic retatrutide — or verified as any specific compound at any stated concentration. The FDA issued over 50 warning letters to retatrutide vendors in 2025 citing violations of the Federal Food, Drug, and Cosmetic Act.

The domain name of this site contains the word "telehealth." This site is not a telehealth service. It is an editorial digest of published pharmacokinetic and clinical-trial literature. No clinician, prescriber, pharmacist, or vendor operates behind this page.